Valproic acid is a deacetylation inhibitor that protects the cardiac function of patients who have experienced myocardial infarction through the Foxm1 pathway, and therefore may also represent a potential therapeutic agent for DCM (Tian et al., 2019). The gene discussed is FOXM1; the disease is familial dilated cardiomyopathy.